CytomX Therapeutics, Inc. financial data

Symbol
CTMX on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 235% % 114%
Debt-to-equity 119% %
Return On Equity 44% %
Return On Assets 20% % 151%
Operating Margin 20% % 286%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 169,435,395 shares 117%
Common Stock, Shares, Outstanding 80,099,889 shares 19%
Entity Public Float $94,400,000 USD -17%
Common Stock, Value, Issued $2,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 165,004,291 shares 94%
Weighted Average Number of Shares Outstanding, Diluted 165,004,291 shares 94%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $113,631,000 USD -10%
Revenue from Contract with Customer, Excluding Assessed Tax $113,631,000 USD -10%
Research and Development Expense $62,284,000 USD -29%
General and Administrative Expense $28,101,000 USD -12%
Operating Income (Loss) $23,246,000 USD 246%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $28,264,000 USD 88%
Income Tax Expense (Benefit) $246,000 USD -80%
Net Income (Loss) Attributable to Parent $28,018,000 USD 103%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $34,185,000 USD -16%
Cash, Cash Equivalents, and Short-term Investments $79,900,000 USD -48%
Accounts Receivable, after Allowance for Credit Loss, Current $1,629,000 USD -51%
Assets, Current $149,217,000 USD 20%
Property, Plant and Equipment, Net $1,721,000 USD -42%
Operating Lease, Right-of-Use Asset $4,814,000 USD -48%
Goodwill $949,000 USD 0%
Other Assets, Noncurrent $51,000 USD -27%
Assets $158,254,000 USD 14%
Accounts Payable, Current $646,000 USD -55%
Employee-related Liabilities, Current $6,419,000 USD -13%
Accrued Liabilities, Current $12,408,000 USD -26%
Contract with Customer, Liability, Current $22,379,000 USD -77%
Liabilities, Current $41,029,000 USD -66%
Contract with Customer, Liability, Noncurrent $5,537,000 USD -83%
Operating Lease, Liability, Noncurrent $0 USD -100%
Other Liabilities, Noncurrent $4,299,000 USD 6.1%
Liabilities $50,865,000 USD -69%
Accumulated Other Comprehensive Income (Loss), Net of Tax $104,000 USD 160%
Retained Earnings (Accumulated Deficit) $682,437,000 USD 3.9%
Stockholders' Equity Attributable to Parent $107,389,000 USD
Liabilities and Equity $158,254,000 USD 14%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $21,043,000 USD 19%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $30,596,000 USD -32%
Common Stock, Shares Authorized 300,000,000 shares 100%
Common Stock, Shares, Issued 80,099,889 shares 19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $162,110,000 USD -7.6%
Deferred Tax Assets, Gross $164,217,000 USD -8.2%
Operating Lease, Liability $9,385,000 USD -33%
Payments to Acquire Property, Plant, and Equipment $119,000 USD 3.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $28,082,000 USD 102%
Lessee, Operating Lease, Liability, to be Paid $10,116,000 USD -36%
Property, Plant and Equipment, Gross $18,698,000 USD 0.28%
Operating Lease, Liability, Current $5,596,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Two $4,387,000 USD -23%
Lessee, Operating Lease, Liability, to be Paid, Year One $5,729,000 USD 2.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $731,000 USD -57%
Deferred Tax Assets, Operating Loss Carryforwards $62,544,000 USD 10%
Unrecognized Tax Benefits $19,994,000 USD 3.2%
Additional Paid in Capital $789,720,000 USD 15%
Amortization of Intangible Assets $36,000 USD 0%
Deferred Tax Assets, Net of Valuation Allowance $2,107,000 USD -37%